vesicle transport through interaction with t-SNAREs 1BGenealiases: VTI1 · VTI1-LIKE · VTI1L · VTI2 · v-SNARE · vti1-rp1
Q-omics provides the consensus-scored VTI1B profile across patient tissues and cancer cell-line models. VTI1B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, VTI1B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, VTI1B RNA expression shows 19,395 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where VTI1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VTI1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VTI1B survival associations across molecular data types. VTI1B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VTI1B RNA expression–survival associations across cancer types. High VTI1B expression shows unfavorable associations in UVM, HNSC, ACC, BLCA and CESC, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for VTI1B RNA expression.
This table summarizes VTI1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VTI1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VTI1B shows lower tumor expression in KIRC, THCA, COAD, BRCA and READ and higher tumor expression in HNSC. The KIRC box plot shows higher VTI1B RNA expression in normal versus tumor tissue (log2 FC = −0.553, t-test p < 0.001).
This table shows molecular features associated with VTI1B in patient tissues and cancer cell lines. In patient samples, VTI1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, VTI1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
